research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.
Search
for
Sort by
Research
180-210 / 1000+ results 
research Alopecia areata
Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
research A New Look at the 5?-Reductase Inhibitor Finasteride
Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Irish dermatologists’ experience with JAK inhibitors in alopecia areata
Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
research Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
research Alopecia areata
research A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database
Alopecia areata in Dubai mostly affects men, often involves autoimmune disorders, and has high healthcare costs, especially for psychological issues.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
New medications could improve treatment for severe alopecia areata in Australia.
research A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
research Dermatological Indications: Alopecia Areata
research Effects of oxytocin receptor agonists on hair growth promotion
OXTR agonists may promote hair growth and be effective for treating hair loss.
research Successful treatment of alopecia areata‐associated trachyonychia with baricitinib
Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.
research Treatments for alopecia areata: a network meta-analysis
The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.
research Human Leukocyte Antigen Class II Alleles Are Associated with Risk of Alopecia Areata
Certain HLA class II alleles increase or decrease the risk of alopecia areata.
research An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
Disease-specific tools better assess alopecia areata's impact on quality of life.
research T H 1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
research Brave New World
"Brave New World" explores the dangers of losing individuality in a future, technologically advanced society that prioritizes collective stability over personal freedom.
research Nail Brace Application
research Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
research Folliculin: A surprising molecular brake in the human hair follicle
Folliculin slows hair growth, and blocking it might help treat hair loss.
research Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Herpes Zoster y COVID 19, coexistencia en un paciente no inmunodeprimido. Reporte de un caso y breve revisión a propósito del mismo.
Herpes zoster can occur with COVID-19 even in healthy individuals.
research Fifty-six years of plastic surgery
Plastic surgery has constantly evolved, improving patient care and expanding techniques, especially after the World Wars.
research Effects of Hair Fibers on Braking Friction Materials
Adding 1% hair fibers to brake materials improves friction and wear, making them more effective.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research The Hair Follicle as an Estrogen Target and Source
Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.